Carrick Therapeutics
Manufacturing · Ireland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Novaucd Belfield Innovation Park Univers...Website
www.carricktherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Carrick Therapeutics
Carrick Therapeutics was founded in 2016, it has a clear vision for cancer patients: to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Whilst other companies bank on a single compound or biological mechanism, Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that are advanced through understanding the mechanisms that cause cancer and resistance, allied with cutting-edge technologies to identify therapeutics and those who would most benefit from them.Explore more
Carrick Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Carrick Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Carrick Therapeutics has new funding data
Check if Carrick Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Carrick Therapeutics
Product Launch: Get notified when Carrick Therapeutics launches new products
Carrick Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Carrick Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Carrick Therapeutics is spiking on competitors!
Earning: See what the market has to say on Carrick Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Carrick Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Carrick Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Carrick Therapeutics.
Carrick Therapeutics financials insights
Gather financial insights about Carrick Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$95M
2022
Series C
$19.5M
Other Financing Round
$35M
Carrick Therapeutics Tech Stack
A closer look at the technologies used by Carrick Therapeutics
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Facilities Relocation / Expansion
Facilities Relocation/Expansion
Funding
Funding
Carrick Therapeutics News & Media
Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer
Two independent Phase 2 trials demonstrate extended progression-free survival in patients without TP53 mutations or without liver metastasesCarrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)
BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor / Cyclin-K glue-degrader. CDK12/13 is implicated in multiple cancer types, as they regulate transcription elongation, RNA splicing, as well as cleavage and polyadCarrick Therapeutics Establishes New Headquarters in Boston, Massachusetts
Appoints David Sutherland, CPA, as Vice President of Finance and Controller Appoints David Sutherland, CPA, as Vice President of Finance and ControllerCarrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination
Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Carrick Therapeutics
Sign Up For FreeTo access detailed company insights
Carrick Therapeutics was founded in 2016, it has a clear vision for cancer patients: to target the molecular pathways that drive the most aggressive and resistant forms of cancer in order to have a major impact on the lives of patients. Whilst other companies bank on a single compound or biological mechanism, Carrick Therapeutics is building an inn... Read More
